Regeneron Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 76 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Regeneron Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Regeneron Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Regeneron Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Regeneron Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Regeneron Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Regeneron Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Regeneron Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

- Evaluate Regeneron Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Regeneron Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Regeneron Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Regeneron Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Regeneron Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Regeneron Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Regeneron Pharmaceuticals, Inc. Snapshot 6
Regeneron Pharmaceuticals, Inc. Overview 6
Key Information 6
Key Facts 6
Regeneron Pharmaceuticals, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Regeneron Pharmaceuticals, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Regeneron Pharmaceuticals, Inc. - Pipeline Products Glance 12
Regeneron Pharmaceuticals, Inc. - Late Stage Pipeline Products 12
Pre-Registration Products/Combination Treatment Modalities 12
Phase III Products/Combination Treatment Modalities 13
Regeneron Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Regeneron Pharmaceuticals, Inc. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Regeneron Pharmaceuticals, Inc. - Drug Profiles 17
aflibercept 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
alirocumab 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
dupilumab 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
sarilumab 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
REGN-1033 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ziv-aflibercept 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
REGN-1908-1909 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
enoticumab 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
nesvacumab 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
REGN-1154 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
REGN-1193 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
REGN-1400 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
REGN-1500 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
REGN-2009 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
REGN-2176-3 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
REGN-2222 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
REGN-1001 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Regeneron Pharmaceuticals, Inc. - Pipeline Analysis 45
Regeneron Pharmaceuticals, Inc. - Pipeline Products by Target 45
Regeneron Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 47
Regeneron Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 48
Regeneron Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 49
Regeneron Pharmaceuticals, Inc. - Recent Pipeline Updates 51
Regeneron Pharmaceuticals, Inc. - Dormant Projects 67
Regeneron Pharmaceuticals, Inc. - Discontinued Pipeline Products 68
Discontinued Pipeline Product Profiles 68
dapiclermin 68
REGN-728 68
REGN-846 68
rilonacept 68
Regeneron Pharmaceuticals, Inc. - Company Statement 70
Regeneron Pharmaceuticals, Inc. - Locations And Subsidiaries 73
Head Office 73
Other Locations & Subsidiaries 73
Regeneron Pharmaceuticals, Inc. - Key Manufacturing Facilities 74
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 76
Disclaimer 76

List of Tables
Regeneron Pharmaceuticals, Inc., Key Information 6
Regeneron Pharmaceuticals, Inc., Key Facts 6
Regeneron Pharmaceuticals, Inc. - Pipeline by Indication, 2014 8
Regeneron Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 10
Regeneron Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 11
Regeneron Pharmaceuticals, Inc. - Pre-Registration, 2014 12
Regeneron Pharmaceuticals, Inc. - Phase III, 2014 13
Regeneron Pharmaceuticals, Inc. - Phase II, 2014 14
Regeneron Pharmaceuticals, Inc. - Phase I, 2014 15
Regeneron Pharmaceuticals, Inc. - Preclinical, 2014 16
Regeneron Pharmaceuticals, Inc. - Pipeline by Target, 2014 46
Regeneron Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 47
Regeneron Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 48
Regeneron Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 50
Regeneron Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 51
Regeneron Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 67
Regeneron Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 68
Regeneron Pharmaceuticals, Inc., Other Locations 73
Regeneron Pharmaceuticals, Inc., Key Manufacturing Facilities 74